Project Grant R44CA291622
Award Date
9/16/24
Completion Date
4/30/28
Dollars Obligated
$1.4M
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Federal Way, WA 98001, USA
Similar Awards
This Project Grant award of $584,872.00 was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to the Fred Hutchinson Cancer Center in Seattle, Washington. The grant supports research to investigate the underlying molecular mechanisms of how mutations in RNA splicing factor genes induce genomic instability in myelodysplastic syndromes (MDS), and to evaluate the therapeutic potential of PARP inhibitors in preclinical MDS models. The project...
This $344,111 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research at Loyola University of Chicago's Health Sciences Campus aimed at understanding and treating myelodysplastic syndromes (MDS), a group of bone marrow failure diseases. The research will investigate using inhibitors of the RIPK1 and TBK1 proteins to restore blood cell production, eliminate mutant hematopoietic stem/progenitor cells, and prevent MDS from...
This $1,398,552 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports Avantgen Inc., a San Diego-based biotechnology company, in conducting preliminary IND-enabling studies for a novel antibody therapy targeting the Jagged-1 pathway in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The key products and services to be delivered under this grant include cell line development, early chemistry and manufacturing controls (CMC)...
This federal Project Grant award for $734,435.00, provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports research to overcome resistance to BH3 mimetic drugs in acute myeloid leukemia (AML). The key objectives are to: Correlate levels of the ADSS2 enzyme, which is involved in AMP biosynthesis, with BH3 mimetic responsiveness in primary AML patient samples, and determine if ADSS2 upregulation drives resistance through clonal selection. Define how...
This $3,157,784 Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) supports the development of SYN101, a first-in-class, immune cell-targeted TGF-beta therapy for cancer patients. The funded work aims to conduct additional in vivo efficacy, safety, and pharmacokinetic studies for SYN101, with the goal of enabling Investigational New Drug (IND) studies. Specifically, the award will assess SYN101's efficacy in humanized mouse tumor models, evaluate its...
The National Cancer Institute awarded a $378,674 Project Grant (CFDA 93.395 - Cancer Treatment Research) to The University of Texas MD Anderson Cancer Center (MD Anderson) to develop a small-molecule inhibitor of the EIF2AK1 protein kinase. The goal is to overcome ineffective erythropoiesis, or impaired red blood cell production, in patients with myelodysplastic syndromes (MDS) characterized by mutations in the SF3B1 gene. This novel therapeutic approach aims to address the severe anemia and...
This Project Grant award, provided by the National Cancer Institute under the Cancer Treatment Research federal grant program (CFDA 93.395), supports research to identify chemical compounds that can inhibit the chromatin reader protein SGF29. This research aims to develop a novel class of anti-leukemia therapeutics, as inhibition of SGF29 has been shown to block leukemogenesis in diverse acute myeloid leukemia (AML) subtypes. The $768,437 award to the Sanford Burnham Prebys Medical Discovery...
This $542,663 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports preclinical research at the University of Texas MD Anderson Cancer Center to investigate the use of BRG1/BRM antagonists as a novel therapy for acute myeloid leukemia (AML) with MLL rearrangement or mutant NPM1. The research aims to determine the efficacy of BRG1/BRM inhibitors and degraders, both as monotherapy and in combination with other agents, in overcoming...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,024,967.00 to Celdara Medical, LLC for the development of CM-HZ01, a novel non-alpha-IL2 therapeutic for the treatment of metastatic melanoma. The project aims to advance CM-HZ01 through Investigational New Drug (IND) filing for clinical testing in metastatic melanoma patients, a condition with limited effective treatment options. The funding supports research to engineer a selective...
The Project Grant award R01CA290480 for $306,623, provided by the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310), is funding research at Wayne State University to enhance treatments for myeloid leukemia associated with Down syndrome (ML-DS). The key objectives are to: 1) determine the role of the Down syndrome bone marrow microenvironment in ML-DS therapy responses, and 2) use hydroxyurea to enhance the anti-leukemic activity of cytarabine...